Moneycontrol PRO
LAMF
LAMF

Ohm Laboratories

Jump to
  • Sun Pharma recalls over 10 lakh boxes of allergy drug in US

  • Ban may hit Ranbaxy's new product launches: JM Fin

  • Pick Ranbaxy below Rs 300; see biz value: Religare

  • Ranbaxy ban: Outsourcing an option, negative EBIDTA seen

  • Ranbaxy plunges 20% on USFDA ban on Toansa API plant

  • USFDA bans Ranbaxy's Toansa API plant, finds mfg violations

  • Mkt won't see runaway rally; like Infy, Wipro: Dilip Bhat

    Prabhudas Lilladher's joint MD Dilip Bhat is positive on Infy, Wipro and Tech Mahindra. He feels at the moment market valuations are not cheap and there won't be any runaway rally in the market.

  • Ranbaxy surges 11% as US plant gets FDA clearance

    In a statement, Ranbaxy said that its New Jersey-based Ohm Labs has received an Establishment Inspection Report (EIR) from the US drug regulator for its December 2012 inspection.

  • Ranbaxy gets USFDA clean chit for Ohm Laboratories

    Drug maker Ranbaxy received a clean chit from the US Food and Drug Administration (USFDA) for its New-Jersey based Ohm Laboratories.

  • Ranbaxy can give high returns but extremely risky: Dron Cap

    Pathik Gandotra of Dron Capital feels Ranbaxy Labs can also give a very high return, but it is extremely risky, he adds.

  • Ranbaxy surges 8% on US FDA approval for Generic Lipitor

    Today, the pharma major Ranbaxy has surged 8.2% on US FDA (Food and Drug Administration) approval for Generic Lipitor. The drug will be manufactured by Ohm Laboratories, reports CNBC-TV18.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347